SCHEMBL1637554

SCHEMBL1637554

CC(=O)Nc1[c]cc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.44
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
DYRK1A Q13627 1/20 0.41
FSCN1 Q16658 1/20 0.41
EPHX1 P07099 1/20 0.40
SMN1; SMN2 Q16637 6/20 0.38
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
LMNA P02545 1/20 0.38
CNR1 P21554 1/20 0.38
ABL1 P00519 1/20 0.37
NR1I2 O75469 1/20 0.37
AHR P35869 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
IDO1 P14902 1/20 0.37
HTT P42858 2/20 0.37
GAA P10253 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1196684 0.81 ALDH1A1 (0.55) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL1195768 0.81 SMN1; SMN2 (0.39) HSD17B10KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL2994051 0.81 NPC1 (0.52) HSD17B10KDM4ENPC1MEN1KMT2A
SCHEMBL17748324 0.78 TDP1 (0.50) HSD17B10DYRK1ASMN1; SMN2MEN1KMT2A
SCHEMBL3891134 0.78 SMN1; SMN2 (0.38) HSD17B10KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL975122 0.78 ALDH1A1 (0.50) HSD17B10KDM4EDYRK1ASMN1; SMN2NPC1
SCHEMBL5645014 0.77 MEN1 (0.44) HSD17B10DYRK1ASMN1; SMN2NPC1RAB9A
SCHEMBL11259370 0.77 PKM (0.42) HSD17B10KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL8845057 0.77 GABRP (0.40) HSD17B10KDM4ESMN1; SMN2NPC1MEN1
SCHEMBL8040685 0.74 PTK2 (0.34) PTK2HSD17B10KDM4EDYRK1AFSCN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 PTK2 2266/4885HSD17B10 2284/4885KDM4E 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.